Aberdeen Group plc Boosts Holdings in IQVIA Holdings Inc. $IQV

Aberdeen Group plc lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,803 shares of the medical research company's stock after buying an additional 5,960 shares during the period. Aberdeen Group plc owned approximately 0.08% of IQVIA worth $22,662,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd grew its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA in the 1st quarter valued at $33,000. Larson Financial Group LLC grew its position in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock valued at $48,000 after buying an additional 144 shares during the last quarter. Finally, Atticus Wealth Management LLC purchased a new position in shares of IQVIA in the 2nd quarter valued at $52,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 2.9%

Shares of NYSE IQV opened at $203.95 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The firm has a 50-day moving average price of $189.44 and a 200 day moving average price of $168.30. The stock has a market capitalization of $34.67 billion, a price-to-earnings ratio of 29.52, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter last year, the business earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on IQV shares. Truist Financial increased their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. HSBC upgraded shares of IQVIA from a "hold" rating to a "buy" rating and increased their price target for the stock from $195.00 to $235.00 in a research note on Thursday. Mizuho increased their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. UBS Group increased their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $234.57.

Insider Activity

In related news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.